The Advisory Committee on Immunization Practices (ACIP) is a group of medical and public health experts that develop recommendations on use of vaccines in the civilian population of the United States…
October 24-25, 2018
Deadline for registration:
Non-US Citizens: September 26, 2018
US Citizens: October 10, 2018
Registration is NOT required to watch the live meeting webcast or to listen via telephone.
Complete list of ACIP recommendations published in the MMWR.
Links to the childhood, adolescent, catch-up, and adult immunization schedules; plus vaccine recording and screening forms.
GRADE (Grading of Recommendations Assessment, Development & Evaluation)
Find tables referenced in ACIP recommendations published in MMWR and learn about GRADE.
General Committee-related Information
Defines ACIP's purpose, authority, and function; its structure, meetings, and compensation; plus costs, reports, and termination.
Membership roster, including chair, executive secretary, voting members, ex officio members, and liaison representatives.
Nominations for future vacancies on ACIP
Procedure for nomination of candidates for ACIP membership.
- Nominations for future vacancies on ACIP
Journal articles about the ACIP.
ACIP Guidance for Economics Studies
Procedures for review of economic analyses to be presented to the ACIP.
ACIP Guidance for Vaccine Recommendations for Pregnant & Breastfeeding Women
Guiding principles for development of ACIP recommendations for vaccination of pregnant and breastfeeding women.
- ACIP Vaccine Acronyms
This ACIP flyer [2 pages] answers questions such as what does the ACIP consider in the vaccine recommendation process, including recommended ages for administration of various vaccines to children?
On November 9, 2017, FDA approved a new hepatitis B vaccine, HEPLISAV-B®, for use in adults 18 years of age and older. HEPLISAV-B® is the first licensed vaccine using a CpG adjuvant* and is administered as two doses given one month apart. Further details on this vaccine’s approval can be found at Vaccines Licensed for Use in the United States.
*Cytosine phosphoguanine (CpG) 1018 adjuvant
June 2018 Meeting Recommendations
ACIP approved the following recommendations by majority vote at its June 2018 meeting:
- Reaffirmed the seasonal influenza recommendations for the 2018-2019 influenza season
- Anthrax vaccine use for post-exposure prophylaxis in a mass vaccination campaign, including:
- The intramuscular route of administration may be used if the subcutaneous route of administration presents clinical, operational, or logistical challenges that may delay or prevent effective vaccination
- Should there be an inadequate supply of anthrax vaccine available for post-exposure prophylaxis, either 2 full doses or 3 half doses of anthrax vaccine absorbed (AVA) may be used to expand vaccine coverage
- In immunocompetent adults aged 18 through 65 years, antimicrobials given in conjunction with vaccine may be discontinued at 42 days after the first vaccine dose or 2 weeks after the last vaccine dose, whichever comes later
These recommendations have been adopted by the CDC Director and will become official once published in MMWR.
- Page last reviewed: April 15, 2016
- Page last updated: July 20, 2018
- Content source: